Jorge Nieva, MD, of the Norris Comprehensive Cancer Center and Keck School of Medicine at the University of Southern California in Los Angeles, joined Lung Cancers Today to discuss his research on lung cancer in young patients. “Young people with lung cancer have a very different pattern of genomic alterations from older people,” Dr. Nieva said in an interview during the IASLC 2024 World Conference on Lung Cancer. “We found that they have an extremely high rate of actionable mutations, and we also found that they’re very commonly non-smokers. So, we asked the ...
Mesothelioma
Advertisement
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
The KEYNOTE-483 trial showed a significant improvement in OS with the addition of pembrolizumab to chemotherapy.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.